[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353172-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353172-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","circulating-tumor-dna-in-merkel-cell-carcinoma-a-precision-biomarker-for-recurrence-detection-and-therapeutic-guidance","Circulating Tumor DNA in Merkel Cell Carcinoma - A Precision Biomarker for Recurrence Detection and Therapeutic Guidance","","Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer with about a 40% recurrence rate, yet reliable blood biomarkers for early recurrence detection and treatment guidance remain limited, particularly in virus-negative tumors. This review synthesizes evidence from 2016–2026 on circulating tumor DNA (ctDNA) as a minimally invasive precision biomarker for minimal residual disease, relapse prediction, and therapy response. ctDNA positivity after curative treatment predicts relapse months before imaging and correlates with tumor burden, enabling risk stratification and earlier intervention, while prospective trials are still needed.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/circulating-tumor-dna-in-merkel-cell-carcinoma-a-precision-biomarker-for-recurrence-detection-and-therapeutic-guidance/353172/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/circulating-tumor-dna-in-merkel-cell-carcinoma-a-precision-biomarker-for-recurrence-detection-and-therapeutic-guidance/353172.png","ImageObject",300,407,{"name":42,"@type":43},"Aldword","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are new biomarkers needed for Merkel cell carcinoma recurrence detection?","Question",{"text":63,"@type":64},"MCC follow-up relies mainly on physical exams and imaging, which can miss microscopic recurrence. Blood biomarkers are unreliable for virus-negative tumors, creating an unmet need for a noninvasive marker across patients.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is ctDNA and how does it support precision oncology in MCC?",{"text":68,"@type":64},"ctDNA consists of tumor-derived fragments of cell-free DNA shed into the bloodstream. Because it reflects real-time tumor burden and can be measured through a blood draw, it helps detect minimal residual disease, predict relapse, and monitor treatment response.",{"name":70,"@type":61,"acceptedAnswer":71},"How can ctDNA monitoring influence treatment decisions and surveillance in MCC?",{"text":72,"@type":64},"ctDNA positivity after curative treatment can predict relapse months ahead of imaging and may distinguish responders from non-responders through serial monitoring. The review also suggests using ctDNA to stratify risk and tailor surveillance intensity, pending prospective validation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353172,1790186548,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336478940917,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Review  \nCirculating Tumor DNA in Merkel Cell Carcinoma: A Precision Biomarker for Recurrence Detection and Therapeutic Guidance Joshua E. Chan  and Lisa C. Zaba *  \nAcademic Editor: Stergios Boussios  \nReceived: 26 March 2026  \nRevised: 13 June 2026  \nAccepted: 18 June 2026  \nPublished: 20 June 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \nDepartment of Dermatology, Stanford University School of Medicine, Stanford, CA 94305, USA; [jechan@stanford.edu](jechan@stanford.edu)  \n* Correspondence: [lisa.zaba@stanford.edu](lisa.zaba@stanford.edu)  \nAbstract  \nBackground/Objectives: Merkel cell carcinoma (MCC) is a rare but aggressive skin cancer with a 40% recurrence rate. However, reliable biomarkers for early recurrence detection or treatment guidance are lacking, especially for virus-negative tumors. Circulating tumor DNA (ctDNA), a fragment of tumor-derived cell-free DNA in blood, has emerged across multiple cancers as a minimally invasive precision biomarker to detect minimal residual disease (MRD); predict recurrence; and monitor treatment response. This review’s objective was to summarize recent advances in ctDNA as a tool for therapeutic decision-making in MCC, contextualized by findings in other malignancies. Methods: A comprehensive literature review was performed, focusing on studies published between 2016 and 2026 that evaluate ctDNA in MCC and other cancers. Key prospective trials, observational studies, and case reports were identified through PubMed and relevant conference proceedings. Data on ctDNA assay methods (tumor-informed vs. tumor-agnostic), clinical sensitivity, lead time for recurrence detection, and predictive value for therapy response were extracted and synthesized. Results: Across cancers such as colorectal, lung, and melanoma, ctDNA positivity after curative treatment predicts relapse months in advance of imaging and can guide adjuvant therapy decisions. In MCC, recent studies demonstrate that ctDNA levels correlate with MCC tumor burden and exhibit high sensitivity and specificity for clinically evident disease. Stage I-III MCC patients who were ctDNA-positive within four months of treatment had a 7.4-fold higher recurrence risk within the subsequent 12–18 months of follow-up. Serial ctDNA monitoring may enable earlier intervention in otherwise asymptomatic ctDNA-positive MCC cases, helping distinguish responders from non-responders. Conclusions: ctDNA is an emerging precision biomarker that offers significant prognostic and surveillance utility in MCC. It enables earlier detection of recurrence, potentially allowing treatment to begin before clinical disease manifests. It also helps stratify patients by risk and treatment response, informing personalized surveillance intensity and therapeutic choices. Integrating ctDNA monitoring into MCC management could improve outcomes by guiding timely interventions, although prospective trials are needed to confirm that ctDNA-guided decisions translate to improved patient survival. Formal cost-effectiveness analyses have not yet been conducted and represent an important area for future investigation.  \nKeywords: Merkel cell carcinoma; circulating tumor DNA; minimal residual disease; surveillance; precision oncology  \n1. Introduction  \nMerkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer with a 40% recurrence rate [1,2] . Current follow-up relies mainly on physical exams and imaging, but these methods can only detect macroscopic disease and may miss early microscopic recurrence. Moreover, MCC lacks universally reliable blood biomarkers: in virus-positive cases (which comprise ~80% of MCC in the U.S.), patients can be monitored with Merkel polyomavirus oncoprotein antibody titers, but this approach is ineffective for the ~20% of virus-negative tumors and requires baseline titers [3]","cbCaie2celQKNzlu","https://ap.wps.com/l/cbCaie2celQKNzlu","pdf",891704,11,"English","# Abstract\n# Introduction\n## Current follow-up limitations in MCC\n## Circulating tumor DNA (ctDNA) as a precision biomarker\n## Assay strategies: tumor-informed vs tumor-agnostic","[{\"question\":\"Why are new biomarkers needed for Merkel cell carcinoma recurrence detection?\",\"answer\":\"MCC follow-up relies mainly on physical exams and imaging, which can miss microscopic recurrence. Blood biomarkers are unreliable for virus-negative tumors, creating an unmet need for a noninvasive marker across patients.\"},{\"question\":\"What is ctDNA and how does it support precision oncology in MCC?\",\"answer\":\"ctDNA consists of tumor-derived fragments of cell-free DNA shed into the bloodstream. Because it reflects real-time tumor burden and can be measured through a blood draw, it helps detect minimal residual disease, predict relapse, and monitor treatment response.\"},{\"question\":\"How can ctDNA monitoring influence treatment decisions and surveillance in MCC?\",\"answer\":\"ctDNA positivity after curative treatment can predict relapse months ahead of imaging and may distinguish responders from non-responders through serial monitoring. The review also suggests using ctDNA to stratify risk and tailor surveillance intensity, pending prospective validation.\"}]","Circulating Tumor DNA in Merkel Cell Carcinoma - A Precision Biomarker for Recurrence Detection and Therapeutic Guidance | PDF",1790103403,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa0f56dc49699c0b01d42ced645f5b91.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8f2f737525709261575832fc9b1fb33.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/336996ba2851dd78cfe9a4a3a42d0771.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/12c1ef68de0364fda089706de6f6fff5.webp",980,1385]